Reference products and why people stop using them — veterinary diabetes glucose monitoring

1. Summary

The domain dossier's own reference-products section (§5) already carries a detailed abandonment record for serial blood-glucose-curve sampling and for off-label FreeStyle Libre use, built from six accuracy PMIDs and one owner-survey PMID. This report adds material the dossier does not yet contain, located in this pass: the portable blood-glucose meter used as the accuracy reference in nearly every study the dossier cites — Zoetis's AlphaTRAK line — has its own small, independent accuracy literature that the dossier does not currently name. Separately, one study varied the FreeStyle Libre's sensor placement site itself (hip versus the standard scapular position) in dogs, and three further peer-reviewed FreeStyle Libre cohorts exist beyond the six PMIDs the dossier already lists, one of which states outright that the device "cannot be recommended for routine monitoring" of a specific patient population. Commercial-timeline material for GluCurve Pet CGM and AlphaTRAK 3's own 2023 US launch was also located via web search but is not carried into this report's Details as a cited finding, because none of the trade-press or manufacturer press-release sources found for it carries a resolvable identifier in this fleet's closed citation vocabulary — that gap is disclosed in §5 rather than papered over with an uncitable source.

2. What Changed

_Baseline (v1). No prior version; this establishes the starting point for future diffs._

3. Details

Sensor placement site — a product-use variable the dossier does not address

Every FreeStyle Libre accuracy study the domain dossier cites uses the standard scapular sensor placement site. One study varied this directly: in 24 non-diabetic dogs undergoing insulin-induced hypoglycemia, FreeStyle Libre 14-day sensors placed simultaneously between the scapulae and over the hip showed a constant bias of 5.6 mg/dL between the two sites (95% limits of agreement -26.3 to 37.5 mg/dL) and correlated with each other (r=0.731, P<.001), measured against blood glucose by AlphaTRAK 2 [1]. The hip site met clinical- but not analytical-accuracy criteria, with 100% of paired hip-site samples falling in Parkes error grid zones A (83%) or B (17%) [1]. The authors' own stated conclusion is a qualified one: hip placement "may be an acceptable alternative to placement between the scapulae," but "the utility in hyperglycemic dogs is unknown" [1] — the study was conducted only in induced hypoglycemia, not spontaneous diabetic hyperglycemia [single-source]. This bears on the dossier's §5 abandonment record from the product-flexibility side rather than the failure side: it does not establish whether an alternate site reduces the skin-reaction or detachment rates the dossier already documents at the scapular site, but it is the only evidence found that the sensor has a viable alternative attachment location at all.

AlphaTRAK — accuracy of the reference meter itself, not just its use as a comparator

The domain dossier's accuracy table uses AlphaTRAK 2 as the blood-glucose comparator in every FreeStyle Libre study it cites, but does not independently source AlphaTRAK's own accuracy. In a prospective study of 60 client-owned cats, a beta prototype of the newer AlphaTRAK 3 meter met ISO 15197:2013 accuracy criteria in 96% of measurements and fell within consensus error grid zones A and B in 100% of measurements against a reference laboratory standard, with a correlation coefficient of 0.99 across the device's stated 20-750 mg/dL range and no significant constant or proportional bias on Bland-Altman analysis [2]. This is the only independently retrieved ISO-accuracy validation of the current-generation AlphaTRAK device found in this pass [single-source]; no comparable independent validation of AlphaTRAK 2 itself — as opposed to its routine use as the comparator device throughout the FreeStyle Libre literature — was found.

Additional FreeStyle Libre cohorts extending the abandonment record

Three further peer-reviewed cohorts, none among the six PMIDs the dossier's §4/§5 already cite, extend its FreeStyle Libre accuracy and tolerability record. In 41 client-owned diabetic cats, sensor placement was well tolerated (70% of cats showed no reaction) and owners were reported as "very satisfied," but only 53% of interstitial readings fell within 15% of the paired AlphaTRAK value, ISO 15197:2013 criteria were not fully met, and median sensor functional life was 10 days (range 1-14) [3] [single-source]. In 7 dogs with diabetic ketoacidosis, FreeStyle Libre readings correlated well with AlphaTRAK 2 (r=0.89), but the mean absolute relative difference was 25.2% (range -70.4% to 101.9%), ISO criteria were not met, and accuracy was measurably worse specifically in the hypoglycemic range [4] [single-source]. Most directly bearing on abandonment: in 10 client-owned cats with diabetic ketosis or ketoacidosis, 81% of high-glycemic-range FreeStyle Libre 2 readings deviated more than 15% from the paired portable-meter value, and the study's own authors concluded, in their own words, "currently this method cannot be recommended for routine monitoring of cats with DK(A)" [5] [single-source] — a stated clinical recommendation against routine use in this specific population, not a limitation left for a reader to infer. A contemporaneous review of the same device across both species states the pattern plainly: FreeStyle Libre "has adequate clinical accuracy both in dogs and cats, even though the accuracy is lower in the hypoglycemic range" [6] — a synthesis consistent with, but not independent evidence beyond, the primary cohorts above [single-source].

4. Sources

[1] Hip sensor location for flash interstitial glucose monitoring system provides adequate clinical accuracy in non-diabetic hypoglycemic dogs — American Journal of Veterinary Research (published 2023; accessed 2026-09-01). PMID 37080253 — https://pubmed.ncbi.nlm.nih.gov/37080253/ [peer-reviewed] [2] High concordance of blood glucose measurement in cats between a beta prototype glucometer device and a reference laboratory standard in a clinical setting — Journal of the American Veterinary Medical Association (published 2024; accessed 2026-09-01). PMID 38190800 — https://pubmed.ncbi.nlm.nih.gov/38190800/ [peer-reviewed] [3] Evaluation of the FreeStyle Libre, a flash glucose monitoring system, in client-owned cats with diabetes mellitus — Journal of Feline Medicine and Surgery (published 2022; accessed 2026-09-01). PMID 35762266 — https://pubmed.ncbi.nlm.nih.gov/35762266/ [peer-reviewed] [4] Evaluation of a flash glucose monitoring system in dogs with diabetic ketoacidosis — Domestic Animal Endocrinology (published 2021; accessed 2026-09-01). PMID 32799040 — https://pubmed.ncbi.nlm.nih.gov/32799040/ [peer-reviewed] [5] Comparison between a Flash Glucose Monitoring System and a Portable Blood Glucose Meter for Monitoring of Cats with Diabetic Ketosis or Ketoacidosis — Animals (published 2024; accessed 2026-09-01). PMID 39409736 — https://pubmed.ncbi.nlm.nih.gov/39409736/ [peer-reviewed] [6] Continuous Glucose Monitoring in Dogs and Cats: Application of New Technology to an Old Problem — Veterinary Clinics of North America: Small Animal Practice (published 2023; accessed 2026-09-01). PMID 36854635 — https://pubmed.ncbi.nlm.nih.gov/36854635/ [peer-reviewed]

5. Sourcing & Gaps

Well established: Nothing here rests on ≥2 independent, non-affiliated primary studies of the same finding — [6] is a review synthesizing the same underlying accuracy literature rather than an independent dataset, so it is marked [single-source] alongside the primary studies it discusses rather than used to upgrade any line to plain fact.

Thin: Every substantive line in §3 rests on exactly one cohort or case series and carries [single-source] — the hip-placement finding (n=24 dogs, induced hypoglycemia only), the AlphaTRAK 3 accuracy finding (n=60 cats, beta prototype device), and each of the three additional FreeStyle Libre cohorts (n=41 cats, n=7 dogs, n=10 cats respectively).

Rescoped from class 3: None. Every proposition in this report is a measured clinical-accuracy or tolerability finding from a named study — no question about what a clinician or owner would do was asked or answered here.

Out of scope: MAUDE narratives (no connector exists in this repository, consistent with the domain dossier's own recorded gap); a systematic multi-clinic AlphaTRAK or GluCurve pricing survey (no connector or federal dataset reaches veterinary device pricing); GluCurve Pet CGM's own accuracy claims and commercial-launch timeline, and AlphaTRAK 3's 2023 US launch and its incompatibility with AlphaTRAK 2 test strips — all of these were located via WebSearch/WebFetch (a December 2025 and a May 2026 ALR Technologies SG Ltd. press release; a July 2026 trade-press continuing-education article stating GluCurve remained Canada-only as of that date, past the company's own "early Q2 2026" US target; a February 2023 trade-press account of the AlphaTRAK 3 launch) but are named here only as context, not carried into §3 or §4, because none of them carries a resolvable identifier in this fleet's closed vocabulary (PMID, NCT, K-number, HCPCS, DOI, CELEX, FR Doc, CFR section) — a company press release or trade-press product announcement has no registry identifier to cite, which this report treats as a reason to disclose the gap rather than a reason to cite a URL as if it were the thing itself.

Not searched vs. not found: An openFDA clearances and recalls check for product code QLG over the 30 days preceding this report's run date returned zero new records in either endpoint — checked and negative, not unsearched. No independent ISO-accuracy validation of AlphaTRAK 2 itself (as opposed to its role as a comparator device) was found; one targeted query was run and returned zero PubMed results, so a broader phrasing may still surface one and this is recorded as not-yet-found rather than a settled negative.

[inference] Whether a hip-site FreeStyle Libre placement would reduce the skin-reaction or detachment rates the domain dossier's §5 documents for the standard scapular site is not tested by [1] or by anything else retrieved in this pass — the hip-site study measured only agreement between sites during induced hypoglycemia, not complication rates. Any read of the hip-site finding as evidence that a redesigned attachment site would improve real-world tolerability is this report's own synthesis, not a conclusion either cited study draws.

6. Claim Candidates